May 29 (Reuters) - Gene therapy maker bluebird bio

on Wednesday named James Sterling as finance chief,

effective June 10, and has been tasked with overseeing a

previously announced revision of its financial statements.

The company said in March it plans to revise its financial

statements for 2022 and the first three quarters of last year

due to accounting errors related to some contract manufacturing

deals.

Sterling, who most recently served as the CFO of

UK-based diagnostics company Renalytix plc ( RNLX ), will

succeed Chris Krawtschuk.